Current Report Filing (8-k)
January 05 2018 - 4:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 1, 2018
CERUS CORPORATION
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
000-21937
|
|
68-0262011
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
2550 Stanwell Drive
Concord, California
|
|
94520
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants Telephone Number, Including Area Code (925)
288-6000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
☐
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communication pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communication pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02
|
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
|
On January 1, 2018, Bruce C. Cozadd, who served as a member of the Board of Directors (the Board) of Cerus Corporation (the
Company) since November 2001, informed the Company of his intention to retire from the Board effective as of January 3, 2018. Mr. Cozadds decision to retire was precipitated by the recent hire of Daniel N. Swisher,
Jr., the Chair of the Companys Board, as the President and Chief Operating Officer of Jazz Pharmaceuticals plc, effective as of January 3, 2018. Mr. Cozadd is a
co-founder
of Jazz
Pharmaceuticals plc and has served as its Chairman and Chief Executive Officer since April 2009. Mr. Cozadds decision to retire was not the result of a disagreement with the Company on any matter relating to the Companys
operations, policies or practices. Mr. Cozadd served as a member of the Compensation Committee and the Audit Committee, a committee for which he served as chair until October 2017.
Item 9.01
|
Financial Statements and Exhibits
|
The following exhibit is furnished with this report:
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CERUS CORPORATION
|
|
|
|
|
Dated: January 5, 2018
|
|
|
|
By:
|
|
/s/ Chrystal N. Menard
|
|
|
|
|
|
|
Chrystal N. Menard
|
|
|
|
|
|
|
Chief Legal Officer and General Counsel
|
3
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Apr 2023 to Apr 2024